Direct Oral Anticoagulants for the Treatment of Cancer-Associated Venous Thromboembolism: A Latin American Perspective

Direct Oral Anticoagulants for the Treatment of Cancer-Associated Venous Thromboembolism: A Latin American Perspective

Venous thromboembolism (VTE) is a leading cause of morbidity and mortality in patients with cancer. On the basis of results from randomized controlled trials, direct oral anticoagulants (DOACs) are now recommended for the treatment of cancer-associated VTE. The decision to use a DOAC requires consid...

Full description

Bibliographic Details
Main Authors: Rodrigo Abensur Athanazio MD, PhD, José Manuel Ceresetto MD, Luis Javier Marfil Rivera MD, Gabriela Cesarman-Maus MD, PhD, Kenny Galvez MD, Marcos Arêas Marques MD, Aldo Hugo Tabares MD, Carlos Alberto Ortiz Santacruz MD, Fernando Costa Santini MD, Luis Corrales MD, Alexander T. Cohen MBBS, MSc, MD, FRACP, FESC
Format: Article
Language:English
Published: SAGE Publishing 2022-03-01
Series:Clinical and Applied Thrombosis/Hemostasis
Online Access:https://doi.org/10.1177/10760296221082988

Internet

https://doi.org/10.1177/10760296221082988

Similar Items